Alpha Cognition (ACOG) Investor presentation summary

Commercial launch and market

• ZUNVEYL is approved for mild-to-moderate Alzheimer’s dementia in adults; described as the first oral Alzheimer’s treatment approved in 15 years.

• More than 30,000 prescriptions were filled through the first 6 launch quarters; Q3 2026 net product revenue was $7.8M, up 30% QoQ.

• Q3 2026 filled prescriptions reached 11,609, up 40% QoQ; cumulative HCP prescribers were 2,438, and 78% of Q3 writers were repeat prescribers.

• The stated $2B commercial opportunity prioritizes long-term care (LTC), which represents 41% of the market; 70% of LTC residents have AD and 70% of LTC lives have access with zero copay.

• Potential Medicare coverage reaches 45% and more than 25M lives without prior authorization; 95% of prescriptions were approved with reimbursement support.

Product profile and differentiation

• ZUNVEYL is a delayed-release galantamine prodrug; its benzoyl ester eliminates AChE inhibition and its gluconate salt increases solubility, with galantamine released after first-pass metabolism.

• Galantamine combines acetylcholinesterase inhibition with nicotinic receptor modulation, increasing acetylcholine availability and potentiating receptor signaling.

• The presentation cites cognitive and functional improvement, behavioral-symptom benefit, and no significant placebo difference across sleep-related outcomes.

• Commercialization uses a focused sales effort: 50 sales representatives, 10 field and payor support staff, and more than 7,100 HCP calls in Q3.

Financial position

• Q3 2026 product gross margin was 94%; cash and equivalents were $37.8M as of September 30, 2026.

• FY 2026 operating expense guidance is $50–54M; operating profitability is expected in 2027.